mat2a inhibitor ide397
mat2a inhibitor ide397: developed by 1 company · 3 clinical trials tracked.
mat2a inhibitor ide397 evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could mat2a inhibitor ide397 → IDYA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| IDEAYA Biosciences, Inc. (IDYA) NSCLC Adenocarcinoma; Solid Tumor | Phase 1 |
Clinical Trials (3)
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors
Primary endpoint: Incidence of Dose-limiting Toxicities (DLTs) of IDE892 (Parts 1 and 3)
A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Anvumetostat in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors
Primary endpoint: Part 1: Number of Participants Experiencing Dose Limiting Toxicities (DLTs)
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors
Primary endpoint: Dose-limiting Toxicities (DLTs) of IDE397
Frequently asked questions
Who is developing mat2a inhibitor ide397?
mat2a inhibitor ide397 is being developed by IDEAYA Biosciences, Inc..
How many clinical trials involve mat2a inhibitor ide397?
BioSniper tracks 3 clinical trials involving mat2a inhibitor ide397.